Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion



Bristol-Myers Squibb said it would acquire biotechnology company Turning Point Therapeutics for $4.1 billion, an effort to deepen the biopharmaceutical giant’s position in lung-cancer treatments.

The purchase price of $76 a share in cash is more than double Thursday’s closing price of $34.16 for Turning Point, but well below the trading price of the San Diego-based company before biotechnology stocks dropped starting last fall.



Source link

Leave a Reply

Your email address will not be published.

%d bloggers like this: